USPTO serial 79432114
NMD PHARMA NEUROMUSCULAR DISORDERS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- FRIZALONE, SARAH O
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 686 means your mark is published in the USPTO Official Gazette and in the 30-day opposition period. If no opposition is filed, prosecution typically continues toward registration or a Notice of Allowance. Monitor the opposition window. After it closes, watch for Notice of Allowance (intent-to-use) or registration (use-based).
Need help with NMD PHARMA NEUROMUSCULAR DISORDERS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Chemical-pharmaceutical preparations for the treatment of rare and genetic diseases; chemical-pharmaceutical preparations for the treatment of neurodegenerative diseases; chemical-pharmaceutical preparations for the treatment of neuromuscular disorders; chemical-pharmaceutical preparations that strengthen neuromuscular transmission and muscle function in patients with neuromuscular disorders; chemical-pharmaceutical preparations for the treatment of neuromuscular disorders caused by compromised skeletal muscle excitability; diagnostic preparations for medical purposes; reagents for medical purposes and for research; preparations for analysis for medical and research purposes; pharmaceutical and medical preparations for the treatment of rare and genetic diseases; pharmaceutical and medical preparations for the treatment of neurodegenerative diseases; pharmaceutical and medical preparations for the treatment of neuromuscular disorders; pharmaceutical and medical preparations that strengthen neuromuscular transmission and muscle function in patients with neuromuscular disorders; pharmaceutical and medical preparations for acute hospital care, namely, chemical-pharmaceutical preparations for the reversal of neuromuscular blockade, chemical-pharmaceutical preparations for the treatment of intensive care unit acquired muscle weakness, chemical-pharmaceutical preparations for the treatment of neuromuscular disorders caused by infections | ACTIVE | — |
| 042 | Scientific and technological services and research, namely, research in the field of medicine and the development of pharmaceutical preparations; industrial analysis and research services in the field of development of pharmaceutical preparations, and in the field of identification of drug candidates; drug discovery services; basic research and clinical research, hereunder in the field of medicine and vaccine development; development of medical treatments related to rare and genetic diseases; development of medical treatments related to neurodegenerative diseases; development of medical treatments related to neuromuscular disorders; development of medical treatments that strengthen neuromuscular transmission and muscle function in patients with neuromuscular disorders; development of medical treatments for acute hospital care | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 4, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Aug 4, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 29, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 6, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 6, 2026 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jul 6, 2026 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jul 6, 2026 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jul 6, 2026 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| May 6, 2026 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| May 6, 2026 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 6, 2026 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Mar 12, 2026 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Mar 12, 2026 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 12, 2026 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Mar 12, 2026 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Mar 12, 2026 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Feb 12, 2026 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jan 19, 2026 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jan 18, 2026 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Dec 4, 2025 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Dec 3, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 3, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 10, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Nov 10, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Nov 8, 2025 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| Sep 4, 2025 | SDRC | SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB | — |